New Content  edit
Get The App!

Loading the player...
Phase 3 RECOURSE trial of TAS-102 vs placebo - Geographic Subgroup analysis
Share URL
Embed Code
Share by Email
Send to social websites
Report this video as inappropriate You can report this video if you think it to be inappropriate, we will review your submission soon. If your reason is not listed here, like copyright infringements, please contact us directly by email. Select your reason
Sexual Content Violent or Repulsive Content
Hateful or Abusive Content Harmful Dangerous Acts
Child Abuse Spam
ASCO 2015 - Eric Van Cutsem, MD, PhD discusses the TAS-102 vs placebo with best supportive care in patients with mCRC - Geographic Subgroups